GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cyclopharm Ltd (ASX:CYC) » Definitions » Valuation Rank

Cyclopharm (ASX:CYC) Valuation Rank


View and export this data going back to 2007. Start your Free Trial

What is Cyclopharm Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cyclopharm Valuation Rank Related Terms

Thank you for viewing the detailed overview of Cyclopharm's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclopharm Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cyclopharm Ltd (ASX:CYC) » Definitions » Valuation Rank
Comparable Companies
MCK COR CAH ASX:SIG SHSE:601607 HSIC HKSE:01099 SHSE:600332 MIL:AMP XSWX:GALE NZSE:EBO SHSE:600998 TSE:7459 SHSE:600511 PDCO TSE:2784 TSE:9987 SHSE:600739 SHSE:600056 TSE:8129
Traded in Other Exchanges
N/A
Address
Unit 4, 1 The Crescent, Kingsgrove, Sydney, NSW, AUS, 2208
Website
https://cyclopharm.com.au
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.